Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Beijing Honghui Meditech Co. Ltd. currently has 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This action is being handled by 1 distinct examiner, SANCHEZ, JUSTIN CHRISTOPHER, in 1 distinct art unit. As the busiest examiner for the company, SANCHEZ, JUSTIN CHRISTOPHER is responsible for 1 pending action. This concentrated prosecution profile indicates a singular focus for the company's current patent efforts.
With only 1 pending office action, the administrative oversight required for this portfolio is minimal. The use of 1 distinct art unit suggests that the pending matter is confined to a specific technical field. SANCHEZ, JUSTIN CHRISTOPHER is the only examiner involved, meaning the company's entire active workload is subject to a single individual's review. This centralization allows for a very focused legal strategy regarding the 1 pending office action. The Biotechnology & Pharmaceuticals area provides the technical context for this singular filing. Practitioners can expect a streamlined process given that 1 distinct examiner manages the entirety of the pending workload.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SANCHEZ, JUSTIN CHRISTOPHER | 1 | 87.3% | +12.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18693036 | Anti-hypoxic/anoxic injury use of a magnolol and/or honokiol aromatic ring amino-substituted derivative, and a pharmaceutical composition | SANCHEZ, JUSTIN CHRISTOPHER | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18693036 | Anti-hypoxic/anoxic injury use of a magnolol and/or honokiol aromatic ring amino-substituted derivative, and a pharmaceutical composition | SANCHEZ, JUSTIN CHRISTOPHER | — |
| Art Unit | Apps |
|---|---|
| 1622 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18693036 | Anti-hypoxic/anoxic injury use of a magnolol and/or honokiol aromatic ring amino-substituted derivative, and a pharmaceutical composition | SANCHEZ, JUSTIN CHRISTOPHER | 1622 | §103§112 | Non-Final OA | — | Pending | Mar 18, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialBeijing Honghui Meditech Co. Ltd. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Justin Christopher Sanchez has the most, with 1 of Beijing Honghui Meditech Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
